Figure 6.

(A). Schematic diagram of the structural composition of KN046@19^F-ZIF-8 nanoplatform and ① Schematic diagram of KN046@19^F-ZIF-8 in response to tumor microenvironment and dissolution of release. ② 19^F NMR signals response to GSH/H⁺. ③KN046@19^F-ZIF-8 combined with dual-targeted immune checkpoint inhibitors for anti-tumor immunotherapy. (B) cumulative release of KN046 from KN046@19^F-ZIF-8 in PBS at different pH (pH =5.0, 6.0, 6.5, 7.4). (C, D) The number of CD4⁺T and CD8⁺T cells in the tumor and spleen was measured and quantified by flow cytometry after treatment with different treatment regimens (PBS, 19^F-ZIF-8, KN046, KN046@19^F-ZIF-8) for the tumor-bearing mice. Data are expressed as mean ± SD (n = 5, *p < 0.05, **p < 0.01,***p < 0.001) (128). Reprinted with permission from Ref. (128).